Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 3/20 | 0.65 |
| ▸ | RAF1 | P04049 | 6/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171330 | 0.92 | DDR2 (0.71) | DDR2RAF1CARM1PRMT6GSK3B | |
| SCHEMBL16990611 | 0.92 | DDR2 (0.54) | DDR2RAF1GSK3BP2RX3 | |
| SCHEMBL15574590 | 0.91 | DDR2 (0.79) | DDR2RAF1CARM1PRMT6GSK3B | |
| SCHEMBL15574694 | 0.90 | DDR2 (0.70) | DDR2RAF1SMN1; SMN2NAMPT | |
| SCHEMBL15574277 | 0.89 | DDR2 (0.68) | DDR2RAF1CARM1PRMT6GSK3B | |
| SCHEMBL16990600 | 0.89 | DDR2 (0.51) | DDR2RAF1GSK3BP2RX3 | |
| SCHEMBL15574596 | 0.88 | DDR2 (0.60) | DDR2RAF1 | |
| SCHEMBL16990652 | 0.87 | DDR2 (0.64) | DDR2RAF1CARM1PRMT6P2RX3 | |
| SCHEMBL16990590 | 0.87 | DDR2 (0.70) | DDR2RAF1GSK3BSMN1; SMN2NAMPT | |
| SCHEMBL15573195 | 0.86 | DDR2 (0.58) | DDR2RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885RAF1 3072/4885CARM1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.